- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01532076
Effectiveness of Adipose Tissue Derived Mesenchymal Stem Cells as Osteogenic Component in Composite Grafts (ROBUST)
Effectiveness of Adipose Tissue Derived Mesenchymal Stem Cells as Osteogenic Component in Composite Grafts Versus Acellular Bone Graft Substitutes for Augmentation in the Treatment of Proximal Humeral Fractures as Model for Fractures of Osteoporotic Bone - a Prospective Randomized First in Men Proof of Principle Trial
Failure rates of up to 30% are reported after proximal humeral fractures despite angular-stable devices. This may devastate not only the functional outcome but also the independence of elderly patients.
To increase bone mineral density and thereby holding-strength augmentation is an option. Autologous bone-graft, as current gold-standard, though is questionable in osteoporosis since osteoprogenitors are dysfunctional and the harvesting-morbidity considerable. Adipose tissue seems an alternative cell-source even in presence of osteoporosis.
Stromal vascular fraction (SVF) cells isolated from lipoaspirates display osteogenic and vasculogenic potential and can be harvested in high numbers. Expansion associated with costly good-manufacturers-practice facilities is avoidable, so are repeated interventions. These cells have been successfully used to generate osteogenic composite grafts with intrinsic vascularity in preclinical models.
For translation into clinical practice after a 20 patient external pilot a prospective randomized controlled trial with 270 patients is planned. For the trial lipoaspiration precedes open reduction and internal fixation in individuals over 60 years presenting with a proximal humeral fracture after low-energy trauma. Cells are isolated (Cellution®800/CRS) and wrapped around hydroxyapatite microgranules after embedding in a fibrin-gel for augmentation of the typical bone-void. Clinical/radiological follow-up is at 6 and 12 weeks for immediate complications and after 6, 9 and 12 months. Functional assessment is performed after 6 weeks, 6 and 12 months using the Quick-Dash- and Constant-Score.
The primary outcome is a reduction in secondary dislocation by 50% during the first postoperative year. Secondary dislocation is diagnosed on plain radiographs by an independent board certified radiologist specialised in musculoskeletal imaging if one or more of the following criteria are met:
- More than 20° varus collapse of the humeral head fragment in relation to the humeral shaft
- Screw penetration through the humeral head
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Basel-Stadt
-
Basel, Basel-Stadt, Switzerland, 4031
- University Hospital Basel
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Presentation with an isolated proximal humeral fracture after a low-energy trauma (e.g. falling from a standing position) and:
indication for open reduction and internal fixation with a proximal humeral locking plate (PHILOS®, Synthes, Switzerland) after low energy trauma
- displacement of more than 1 cm between fragments and/or
- angulation of 45° or more between the fragments and/or
- dislocation of the greater tuberosity of 5 mm or more and/or
- patient specific factors like high functional demand etc
- age > 50 years
- postmenopausal status (i.e. 12 continuous month without menstruation)
- informed consent in surgery and study participation
Exclusion Criteria:
- Psychiatric disorder severely impairing co-operation (dementia mini mental Status (MMS) <24, schizophrenia, major depression)
- Pathological fractures caused by other conditions
- Fracture-related nerve injury
- Malignancies under current treatment (i.e. chemotherapy, radiotherapy etc.)
- BMI <20 kg/m2
- Known hypersensitivity to one of the graft components
- Participation in a clinical trial within 3 month before enrolment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: cellularized composite graft augmentation
lipoaspiration by experienced plastic surgeon, isolation of SVF cells using a Cellution/CR800® cell isolation device and single use kits (Cytori Therapeutics Inc., San Diego) during open reduction and internal fixation, augmentation of bone with cell-seeded bone graft substitute;
|
liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules
Other Names:
|
ACTIVE_COMPARATOR: Control acellular composite graft augmentation
open reduction internal fixation (ORIF) of the fracture, augmentation with acellular bone graft substitute.
|
Open reduction and internal fixation using acellular augmentation with fibrin embedded granulated hydroxyapatite
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development of secondary dislocation within 12 months postoperative
Time Frame: 12 months postoperative
|
Secondary dislocation within the first year postoperative on plain radiographs in ap. and Neer projections diagnosed by an independent radiologist specialized in musculoskeletal imaging in case of
|
12 months postoperative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional outcome 6 weeks, 6 and 12 months after fixation
Time Frame: 12 months postoperative
|
Functional outcome 6 weeks, 6 and 12 months after fixation: the functional outcome will be recorded by the Quick Dash Score and the Constant at each follow up visit and compared between the two groups.
Additionally, pain at either surgical site will be recorded via the visual analogue scale.
|
12 months postoperative
|
Safety
Time Frame: 12 months postoperative
|
safety: all adverse reactions will be recorded and analysed to assess the safety of the approach in a typical patient population.
|
12 months postoperative
|
bone mineral density
Time Frame: 12 months postoperative
|
bone mineral density: in case of implant removal (see below) a 100 mm3 bone biopsy will be taken from the grafted area and analysed with MicroCT (micro computed tomography) for bone mineral density.
|
12 months postoperative
|
Histology
Time Frame: 12 months postoperative
|
histological assessment of qualitative and quantitative bone formation: bone biopsies will - after MicroCT assessment - be decalcified and histologically analysed using standard techniques and image quantification
|
12 months postoperative
|
Dose-response
Time Frame: 12 months postoperative
|
establishment of a dose response relationship between number of implanted cells an bone quantity in microCT and histologically via image quantification: retrospectively the quantitative measures of bone formation will be correlated to the number of implanted cells and their clonogenicity
|
12 months postoperative
|
Collaborators and Investigators
Investigators
- Principal Investigator: Franziska Saxer, MD, University Hospital, Basel, Switzerland
- Principal Investigator: Marcel Jakob, MD, University Hospital, Basel, Switzerland
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 348/10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporotic Fractures
-
University Hospital, Clermont-FerrandUniversité d'Auvergne; European Regional Development Fund; Regional Council of... and other collaboratorsUnknown
-
Jiawei JiangRecruitingOsteoporotic Fracture of VertebraChina
-
Universidad de ValparaisoPontificia Universidad Catolica de Valparaiso; Centro Gerópolis UV, Valparaíso and other collaboratorsRecruitingOsteoporotic FracturesChile
-
University of Wisconsin, MadisonCompletedOsteoporotic FracturesUnited States
-
Suzhou Municipal HospitalRecruiting
-
Groupe Hospitalier Paris Saint JosephHôpital Sainte-Marie ParisActive, not recruitingOsteoporotic FracturesFrance
-
Optimus Clinical ResearchCareFusionCompletedVertebral Compression Fractures | Osteoporotic Vertebral Compression Fractures | Acute Vertebral FracturesAustralia
-
University of SaskatchewanSaskatchewan Health Research Foundation; Saskatchewan Centre for Patient-Oriented...Recruiting
-
Assiut UniversityUnknownOsteoporotic Fracture of Vertebra
-
Nexilis AGTerminatedOsteoporotic Fracture of VertebraAustria
Clinical Trials on Cellularized composite graft augmentation
-
Akademicka Poliklinika StomatologicznaCamlog Foundation; Wrocław Medical UniversityCompleted
-
University of ZurichCompleted
-
Universitat Internacional de CatalunyaNot yet recruitingEdentulous Alveolar Ridge | Soft Tissue Atrophy | Mucogingival Deformity on Edentulous Ridge
-
Stryker Trauma GmbHSt. Boniface Hospital; Fowler Kennedy Sport Medicine Clinic; Kelsey-Seybold Clinic and other collaboratorsCompleted
-
Ethisch Comité UZAUniversity Hospital, Ghent; Universitair Ziekenhuis BrusselUnknownLimbal Stem Cell DeficiencyBelgium
-
Gazi UniversityCompletedGingival Recession | Tooth Abrasion
-
Cairo UniversityNot yet recruitingAtrophic Maxilla | Vertical Ridge DeficiencyEgypt
-
International Piezosurgery AcademyUniversity of TriesteCompletedAlveolar Bone LossItaly
-
Universitat Internacional de CatalunyaOsteology FoundationUnknownTooth Loss | Recession, Gingival
-
University of Firenze and Siena, Napoli, ItalyCompletedOral Soft Tissue ConditionsItaly